Factor P Antibody (Monoclonal - #2)

A murine monoclonal antibody to an epitope on Factor P.


Product Specifications

Citations 9
Clonality

Monoclonal

Immunogen Purified human protein.
Applications See citations and technical data sheet for application info.
Concentration 1.0-1.2 mg/mL
Conjugate Unconjugated
Cross Reactivity

Human

Ordering Information

For Research Use Only in the United States. Not for use in diagnostic procedures.
Catalog Number A235
Catalog Number (CE) N/A
Size 100 µl
Price (USD) $375.00
Price (EURO) 340,00 €

Contact us

US Phone+1 (858) 552 1100
EU Phone+353 (91) 412 474
US Emailcontact-us@quidelortho.com
EU Emailcontact-emea@quidelortho.com

Specifications

Description

A murine monoclonal antibody to an epitope on Factor P.

Size 100 µl
Concentration

1.0-1.2 mg/mL

Applications See citations and technical data sheet for application info.
Form Liquid. Borate Buffered Saline (pH 8.4 ± 0.2), with ≤ 0.1% Sodium Azide.
Clonality Monoclonal
Immunogen Purified human protein.
Conjugate Unconjugated
Cross Reactivity Human
Isotype IgG1k
Purity ≥ 95% by SDS PAGE
Source

Mouse

Specificity This monoclonal antibody was raised against purified human Factor P. It does not inhibit function of Factor P.
Storage

Short term (30 days) 4˚C. Long term at or below –20˚C.

Background

The function of Properdin (Factor P) is to stabilize the alternative pathway convertase. Its binding to C3bBb extends the half-life of the complex. The concentration in plasma is approximately 20 μg/mL. Factor P has a molecular weight of 224 kDa, consisting of four identical chains of approximately 53 kDa molecular weight. The alternative complement pathway provides innate protection against microbial agents in the absence of specific antibody. The activation of this complement pathway can be triggered by a variety of substances, including microbial polysaccharides or lipids, gram-negative bacterial lipopolysaccharides, and surface determinants present on some viruses, parasites, virally infected mammalian cells and cancer cells. In autoimmune diseases, the alternative complement pathway may contribute directly to tissue damage.